no credit card required  No credit card. No commitment.
 5000 plus G2 reviews  5000+ G2 reviews
Company logo
Oxford Biomedica
Oxford Biomedica

Oxford Biomedica's financial review

Oxford Biomedica's Revenue (Yearly)

84M

Employees

720

Total Funding

222.1M

Last Funding Round

53.5M

lse

OXB

See all Oxford Biomedica's financial information

Oxford Biomedica information

Oxford Biomedica (LSE: OXB) is an innovative leading viral vector specialist focused on delivering life changing therapies to patients. Based in Oxfordshire (UK) and greater Boston (US), we work across key viral vector delivery systems including those based on lentivirus, adeno-associated virus (AAV) and adenovirus, providing innovative solutions to meet our partner's process development, analyti...
Oxford Biomedica (LSE: OXB) is an innovative leading viral vector specialist focused on delivering life changing therapies to patients. Based in Oxfordshire (UK) and greater Boston (US), we work across key viral vector delivery systems including those based on lentivirus, adeno-associated virus (AAV) and adenovirus, providing innovative solutions to meet our partner's process development, analytical development, and manufacturing needs. Our well-established and industry leading lentiviral vector platform, LentiVector® platform, is used to develop product candidates in-house, before seeking partners to take the products into clinical trials. Our platform, IP, patents, and know-how, along with our 25 plus years of expertise in applying its lentiviral vector technology, has taken us from pioneers in the field to the sector leader we are today. OXB Solutions, our US based best-in-class AAV manufacturing and innovation business is raising the bar in AAV development and manufacturing solutions. Offering full scope process development and GMP operations using a commercially ready ‘plug and play' platform. The execution and data speak for itself: - HEK293 suspension process scaled up from 2L to 2000L - Dual plasmid system with optimised transfection demonstrating E15 vg/L in bioreactors - Demonstrated >90% fully intact vector - Analytical toolbox with 40+ methods developed and qualified in-house - Delivered greater than 45 500L GMP batches in the last three years - 6 successful IND regulatory filings We drive credible science and innovation to help realise incredible results, making us the ideal cell and gene therapy vector partner. Discover how by visiting our website.

Oxford Biomedica industries

Gene therapy
Immunotherapy
Viral vector gmp manufacturing
Research

Oxford Biomedica's financial review

Oxford Biomedica's Revenue (Yearly)

84M

Employees

720

Total Funding

222.1M

Last Funding Round

53.5M

lse

OXB

See all Oxford Biomedica's financial information

Employees

Senior Maintenance Technician
Lead Metrology Technician
Vice President - Head of Investor Relations
CEO & Board Chair, OXB Solutions LLC
Quality Control Analyst

Prospect on LinkedIn

Find verified emails and direct dial mobile numbers of contacts on LinkedIn, and sync them with your CRM instantly
Download ExtensionRepresents linkedin prospector
Browse Apollo's Directories

Why our clients choose Apollo

“Apollo completely changed the game for us. It allowed us to identify relevant targets that are ready to scale and reach out to them at the exact right time.”
Image of Erik Straub

Erik Straub

Head of Product, Kickfurther

“Using Apollo.io, we've solved the biggest problem for every business, the lead problem. We are now constrained by sales time and no longer lack interested prospects.”
Image of Michael Transon

Michael Transon

CEO, Victorious

Apollo gives you all the company insights you need

Free to get started, easy to add your whole sales team, commit to monthly or annual plans. We make it easy to get started.